Marie-eve Beaulieu
Barcelona, CT, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Corrigendum: Reducing MYC's transcriptional footprint unveils a good prognostic gene signature in melanoma.
Journal: Genes & development
Published: September 02, 2025
MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer.
Journal: Cell reports
Published: June 18, 2025
EV20/Omomyc: A novel dual MYC/HER3 targeting immunoconjugate.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: November 03, 2023
MYC targeting by OMO-103 in solid tumors: a phase 1 trial.
Journal: Nature medicine
Published: February 07, 2023
Targeting MYC-driven lymphoma: lessons learned and future directions.
Journal: Cancer drug resistance (Alhambra, Calif.)
Published: November 18, 2022
Reducing MYC's transcriptional footprint unveils a good prognostic gene signature in melanoma.
Journal: Genes & development
Published: September 05, 2022
MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding.
MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding.
Journal: Cancer research communications
Published: October 26, 2021
MYC, MYCL, and MYCN as therapeutic targets in lung cancer.
Journal: Expert opinion on therapeutic targets
Published: February 01, 2020
The Wnt signaling receptor Fzd9 is essential for Myc-driven tumorigenesis in pancreatic islets.
Journal: Life science alliance
Published: July 18, 2019
Last Updated: 09/26/2026